Aktuellt
SENASTE
Q4 marked a strong end to 2021, with the results topping our expectations. We think SyntheticMR is well positioned heading into 2022; with plentiful growth levers lined up, the theme for the year will be execution and delivering its high growth ambitions, in our view. We leave our estimates largely unchanged following the Q4 report and reiterate our DCF-based fair value range of SEK 41-54 per share.
LÄS MER
